1. Home
  2. ZYME vs PLPC Comparison

ZYME vs PLPC Comparison

Compare ZYME & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • PLPC
  • Stock Information
  • Founded
  • ZYME 2003
  • PLPC 1947
  • Country
  • ZYME United States
  • PLPC United States
  • Employees
  • ZYME N/A
  • PLPC N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • PLPC Water Sewer Pipeline Comm & Power Line Construction
  • Sector
  • ZYME Health Care
  • PLPC Industrials
  • Exchange
  • ZYME Nasdaq
  • PLPC Nasdaq
  • Market Cap
  • ZYME 846.1M
  • PLPC 670.0M
  • IPO Year
  • ZYME 2017
  • PLPC N/A
  • Fundamental
  • Price
  • ZYME $11.43
  • PLPC $142.64
  • Analyst Decision
  • ZYME Buy
  • PLPC
  • Analyst Count
  • ZYME 7
  • PLPC 0
  • Target Price
  • ZYME $19.50
  • PLPC N/A
  • AVG Volume (30 Days)
  • ZYME 449.0K
  • PLPC 47.9K
  • Earning Date
  • ZYME 05-08-2025
  • PLPC 07-30-2025
  • Dividend Yield
  • ZYME N/A
  • PLPC 0.56%
  • EPS Growth
  • ZYME N/A
  • PLPC N/A
  • EPS
  • ZYME N/A
  • PLPC 7.89
  • Revenue
  • ZYME $93,384,000.00
  • PLPC $601,351,000.00
  • Revenue This Year
  • ZYME $34.23
  • PLPC N/A
  • Revenue Next Year
  • ZYME $68.78
  • PLPC N/A
  • P/E Ratio
  • ZYME N/A
  • PLPC $18.08
  • Revenue Growth
  • ZYME 85.05
  • PLPC N/A
  • 52 Week Low
  • ZYME $8.21
  • PLPC $109.01
  • 52 Week High
  • ZYME $17.70
  • PLPC $154.90
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 45.92
  • PLPC 56.02
  • Support Level
  • ZYME $11.46
  • PLPC $133.27
  • Resistance Level
  • ZYME $11.81
  • PLPC $147.50
  • Average True Range (ATR)
  • ZYME 0.59
  • PLPC 3.78
  • MACD
  • ZYME -0.05
  • PLPC 0.86
  • Stochastic Oscillator
  • ZYME 27.62
  • PLPC 65.85

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About PLPC Preformed Line Products Company

Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.

Share on Social Networks: